Research Update

RNS Number:9296Q
Ardana PLC
07 September 2005


CLINICAL DEVELOPMENT OF ARDANA'S TEVERELIX LONG ACTING (LA) IN PROSTATE CANCER
CONTINUES ON TRACK FOLLOWING PRE-IND APPLICATION MEETING WITH THE UNITED STATES
FOOD AND DRUG ADMINISTRATION (FDA)


Edinburgh, UK, 7 September 2005;  Ardana plc (LSE:ARA) the emerging
pharmaceutical company focused on improving human reproductive health, today
announces that the company has had a pre-Investigational New Drug (IND)
application meeting with the FDA to discuss the development for prostate cancer
of its lead compound Teverelix LA, a GnRH antagonist.

Recent results from two Phase II studies in patients with prostate cancer have
been detailed in previous press releases. In these studies Teverelix LA
successfully suppressed serum testosterone to the required levels for treatment.

An additional Phase II study outside the USA is expected to commence within the
coming month and results from this study should be available in the first half
of 2006.

The FDA has confirmed that serum testosterone levels can serve as a reliable
surrogate marker for efficacy in the treatment of prostate cancer.  The meeting
reached agreement on the path forward for the development of Teverelix LA for
the treatment of prostate cancer, which will allow Ardana to meet its
registration timelines and previously announced launch target of the end of
2009.  Ardana is planning to submit to the FDA its first study to be performed
under an IND in the pursuit of this indication within the next few months.

Dr Maureen Lindsay, CEO Ardana, said "We are very encouraged by the feedback we
have had from the FDA.  The clinical development and launch for prostate cancer
is on track according to our original schedule. Teverelix LA is also being
developed for the treatment of Benign Prostatic Hyperplasia (BPH) and
Endometriosis. We expect to be reporting shortly on a further meeting with the
FDA about BPH. "


For more information contact:
Ardana                                 Financial Dynamics
Maureen Lindsay                        (corporate/financial media relations)
Tel: + 44 (0) 131 226 8550             Julia Phillips/Davina Langdale
                                       Tel: [phone]

                                       NB Public Relations
                                       (trade/technical media relations)
                                       Nicki Brimicombe
                                       Tel: + 44 (0)1883 732353



About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $23.8
billion market.

Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
out-licensing to maintain a robust pipeline.

Ardana's four lead products are summarised below:



  * Striant(TM) SR, a testosterone replacement therapy that has already been
    launched by Ardana through its own sales force in the UK as a treatment for
    men with hypogonadism and for which Ardana has marketing rights in Europe;
  * Teverelix LA, in development for three initial indications (prostate
    cancer, benign prostatic hyperplasia and endometriosis);
  * Testo Bi-gel, a trans dermal testosterone delivery system in development
    for the treatment of male hypogonadism, shortly to enter Phase II trials;
  * Invicorp, an injectable combination drug treatment for erectile
    dysfunction, for which Ardana has marketing and manufacturing rights in
    Europe.





In addition, Ardana has a strong portfolio of follow-on products in development.

Ardana completed its IPO on the London Stock Exchange in March 2005 raising #21
million.

For further information please see www.ardana.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RESVQLFBEKBFBBL